Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTX NASDAQ:FBRX NYSE:JATT NASDAQ:ZURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.83+1.7%$1.94$1.50▼$2.79$83.56M1.69100,766 shs124,893 shsFBRXForte Biosciences$11.48+8.7%$10.85$4.11▼$28.68$142.70M2.6964,100 shs153,467 shsJATTJATT Acquisition$2.00-1.0%$1.70$7.80▼$12.38$34.50MN/A41,322 shs255,571 shsZURAZura Bio$1.92-4.0%$1.71$0.97▼$5.07$124.84M-0.02496,146 shs339,750 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio0.00%-12.62%-10.00%-10.00%-9.55%FBRXForte Biosciences0.00%-6.22%-8.73%-22.35%+45.05%JATTJATT Acquisition0.00%-9.09%+16.28%+66.67%-45.95%ZURAZura Bio0.00%-9.09%+20.48%+66.67%-45.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.83+1.7%$1.94$1.50▼$2.79$83.56M1.69100,766 shs124,893 shsFBRXForte Biosciences$11.48+8.7%$10.85$4.11▼$28.68$142.70M2.6964,100 shs153,467 shsJATTJATT Acquisition$2.00-1.0%$1.70$7.80▼$12.38$34.50MN/A41,322 shs255,571 shsZURAZura Bio$1.92-4.0%$1.71$0.97▼$5.07$124.84M-0.02496,146 shs339,750 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio0.00%-12.62%-10.00%-10.00%-9.55%FBRXForte Biosciences0.00%-6.22%-8.73%-22.35%+45.05%JATTJATT Acquisition0.00%-9.09%+16.28%+66.67%-45.95%ZURAZura Bio0.00%-9.09%+20.48%+66.67%-45.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio 4.00Strong Buy$10.00446.45% UpsideFBRXForte Biosciences 3.00Buy$68.00492.33% UpsideJATTJATT Acquisition 0.00N/AN/AN/AZURAZura Bio 3.00Buy$14.00629.17% UpsideCurrent Analyst Ratings BreakdownLatest JATT, FBRX, ZURA, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025ZURAZura BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.008/15/2025ZURAZura BioOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $16.008/15/2025ZURAZura BioChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.008/11/2025ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$180K464.21N/AN/A$0.23 per share7.96FBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/AJATTJATT AcquisitionN/AN/A$0.07 per share27.08($0.53) per shareN/AZURAZura BioN/AN/AN/AN/A$2.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-77.75%-68.13%11/14/2025 (Estimated)FBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/AZURAZura Bio-$45.39M-$0.70N/AN/AN/AN/A-49.11%-40.06%11/6/2025 (Estimated)Latest JATT, FBRX, ZURA, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/14/2025Q2 2025ZURAZura Bio-$0.19-$0.17+$0.02-$0.17N/AN/A8/8/2025Q2 2025ENTXEntera Bio-$0.11-$0.06+$0.05-$0.06N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AZURAZura BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.4710.47FBRXForte BiosciencesN/A11.7411.74JATTJATT AcquisitionN/A0.150.15ZURAZura BioN/A8.408.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%FBRXForte Biosciences77.63%JATTJATT Acquisition47.97%ZURAZura Bio61.14%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio10.38%FBRXForte Biosciences5.90%JATTJATT Acquisition20.00%ZURAZura Bio22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio2045.66 million40.92 millionOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableZURAZura Bio365.02 million50.65 millionOptionableJATT, FBRX, ZURA, and ENTX HeadlinesRecent News About These CompaniesHead to Head Review: Zura Bio (NASDAQ:ZURA) and Genmab A/S (OTCMKTS:GNMSF)September 15 at 4:05 AM | americanbankingnews.comAllostery Investments LP Acquires 714,258 Shares of Zura Bio Limited $ZURASeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Raises Stake in Zura Bio Limited $ZURASeptember 4, 2025 | marketbeat.comZura Bio Unveils Updated Corporate PresentationSeptember 4, 2025 | tipranks.comZura Bio Limited (NASDAQ:ZURA) Receives $14.00 Consensus Price Target from BrokeragesSeptember 4, 2025 | americanbankingnews.comZura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Buy" from AnalystsSeptember 2, 2025 | marketbeat.comFY2025 EPS Estimates for Zura Bio Boosted by HC WainwrightAugust 23, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC WainwrightAugust 21, 2025 | marketbeat.comZura Bio price target lowered to $2 from $3 at H.C. WainwrightAugust 19, 2025 | msn.comQ1 Earnings Estimate for Zura Bio Issued By Leerink PartnrsAugust 19, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at OppenheimerAugust 17, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan CapitalAugust 17, 2025 | marketbeat.comZura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPSAugust 16, 2025 | marketbeat.comZura Bio price target lowered to $16 from $17 at OppenheimerAugust 15, 2025 | msn.comZura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate UpdatesAugust 14, 2025 | businesswire.comRobert Lisicki on Living Up to Zura Bio’s Heroic NamesakeJuly 31, 2025 | pharmexec.comP3 Penny Stocks With Market Caps Over $70M Worth WatchingJuly 18, 2025 | finance.yahoo.comZura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 18, 2025 | finance.yahoo.comZura Bio Announces Chief Financial Officer TransitionJuly 1, 2025 | businesswire.comZura Bio shareholders approve board nominees and auditorMay 24, 2025 | investing.comZura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativaMay 21, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJATT, FBRX, ZURA, and ENTX Company DescriptionsEntera Bio NASDAQ:ENTX$1.83 +0.03 (+1.67%) Closing price 04:00 PM EasternExtended Trading$1.82 -0.02 (-0.82%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.Forte Biosciences NASDAQ:FBRX$11.48 +0.92 (+8.71%) Closing price 04:00 PM EasternExtended Trading$11.55 +0.07 (+0.61%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.JATT Acquisition NYSE:JATT$2.00 -0.02 (-0.99%) As of 09/12/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Zura Bio NASDAQ:ZURA$1.92 -0.08 (-4.00%) Closing price 04:00 PM EasternExtended Trading$1.88 -0.03 (-1.82%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
